Medicines

Ivonescimab (PD-1/VEGF BsAbs,AK112),  developed independently by Akeso, Inc, is the world’s first PD-1/VEGF bispecific antibody for clinical trail. Ivonescimab injection(AK112) has received 3 breakthrough therapy designation(BTD) for NSCLC.

ALCOA and ALCOA PLUS principles are for Data integrity.
ALCOA: Attributable, Legible, Contemporaneous, Original, Accurate.
ALCOA PLUS: Complete, Consistent, Enduring, Available When Needed.

On June 5th, Beijing VDJBio Co., Ltd.(VDJBio) announced the completion of its Series C financing round.VDJ-001 is a recombinant humanized monoclonal antibody injection that targets interleukin-6 (IL-6) receptors.

SOP for Responsibilities of the Production Department. All personnel in the Production Department shall implement their respective responsibilities, and the head of the Production Department shall be responsible for supervising the implementation of these responsibilities.

Here is SOP for Responsibilities of the Head of the Production Department for pharmaceutical company.

Apr, 2023. AstraZeneca’s Gefurulimab injection(ALXN1720) obtains the Implied License from CDE for generalized myasthenia gravis clinical trial.

On March 10th, 2023， Beijing InnoCare announced that its independently developed BCL2 inhibitor ICP-248 completed the first subject administration in China. ICP-248 is a new oral highly selective BCL2 inhibitor independently developed by InnoCare. It is intended for the treatment of malignant hematological tumors such as non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL) as a monotherapy or in combination with other drugs such as BTK inhibitors. ICP-248 is currently being investigated for B-cell malignancies, malignant hematologic tumors, and hematologic tumors. BCL2 is an oncogene with a significant role in…

Jan, 2023, Simnotrelvir Tablets/Ritonavir Tablets (co-packaged) submitted by Hainan Simcere Pharmaceutical Co., Ltd. received special drug approval as class 1 innovative drug for emergency application at China National Medical Products Administration (NMPA) with conditional requirements.

Reasons for controlling the speed of intravenous drip are as follows: a) to avoid phlebitis and even venous thrombosis risk of with vascular irritating drugs; b)to avoid serious adverse reactions caused by high peak blood concentration; c) to avoid risk of pulmonary edema caused by blood volume increases. Here are 10 Antibiotics with Infusion Time More Than 60 Minutes. 

The incidence of seborrheic dermatitis is about 1% to 3%, and the incidence of young people is 3% to 5%.Ketoconazole, Ciclopirox Olamine,Glucocorticoids，Pimecrolimus and Tacrolimus can be used for the treatment of Seborrheic dermatitis.